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Edited by Varda RotterAbstract Short 21-mer double-stranded/small-interfering
RNAs (ds/siRNAs) were designed to target bcr-abl mRNA in
chronic myelogenous leukemia. The ds/siRNAs were transfected
into bcr-abl-positive K-562 (derived from blast crisis chronic
myelogenous leukemia), using lipofectamine. Penetrating of
ds/siRNAs into the cells was detected by ﬂuorescent confocal
microscopy, using ﬂuorescein-labeled ds/siRNAs. The cells were
treated with mix of three siRNA sequences (3 60 nM) during 6
days with three repetitive transfections. The siRNA-treatment
was accompanied with signiﬁcant reduction of bcr-abl mRNA,
p210, protein tyrosine kinase activity and cell proliferation
index. Treatment of cells with Glivec (during 8 days with four
repetitive doses, 180 nM single dose) resulted in analogous
reduction of cell proliferation activity, stronger suppression of
protein tyrosine kinase activity, and very low reduction of p210.
siRNA-mix and Glivec did not aﬀect signiﬁcantly the viability of
normal lymphocytes. Microarray analysis of siRNA- and Glivec-
treated K-562 cells demonstrated that both pathways of bcr-abl
suppression were accompanied with overexpression and suppres-
sion of many diﬀerent oncogenes, apoptotic/antiapoptotic and
cell proliferation factors. The following genes of interest were
found to decrease in relatively equal degree in both siRNA- and
Glivec-treated cells: Bcd orf1 and orf2 proto-oncogene, chroma-
tin-speciﬁc transcription elongation factor FACT 140-kDa
subunit mRNA, gene encoding splicing factor SF1, and mRNA
for Tec protein tyrosine kinase. siRNA-mix and Glivec provoked
overexpression of the following common genes: c-jun proto-
oncogene, protein kinase C-a, pvt-1 oncogene homologue (myc
activator), interleukin-6, 1-8D gene from interferon-inducible
gene family, tumor necrosis factor receptor superfamily (10b),
and STAT-induced STAT inhibitor.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.1. Introduction
The bcr-abl oncogene is a result of a reciprocal transloca-
tion between the long arms of chromosome 9 and 22, en-
coding a cytoplasmic fusion oncoprotein with tyrosine kinase* Corresponding author. Fax: +81-87-8694113.
E-mail address: r.bakalova-zheleva@aist.go.jp (R. Bakalova).
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doi:10.1016/j.febslet.2004.06.048activity that inhibits apoptosis and triggers malignant trans-
formation. Bcr-abl fusion is a single causative abnormality in
chronic myelogenous leukemia (CML), at least in chronic
phase, making it a unique model for development of molec-
ular targets for disease control [1–3]. Gene or protein tar-
geting of the chimeric fusion is a promising way to eliminate
the bcr-abl-positive cells speciﬁcally, without any inﬂuence on
the viability of normal cells. Increasing knowledge on bcr-abl
resulted in a design of several novel therapeutic approaches,
including highly speciﬁc tyrosine kinase inhibitors (as Glivec
and pyrido[2,3-d]pyrimidine derivative PD180970), single-
stranded antisense oligo-RNA and oligo-DNA substances,
and immunomodulation [1–4]. Recently, it has been reported
that short double-stranded/small-interfering RNA molecules
(ds/siRNA), targeting to bcr-abl abnormality, are also
promising tool for control of the chimeric fusion protein ex-
pression [5–7].
It has been found that the inhibition of bcr-abl synthesis by
antisense oligo-DNAs or conventional drugs is accompanied
with cross-talk with other oncogenes (e.g., telomerase) and
telomere-associated proteins (e.g., tankyrase, TRF1 and Tin2)
[8,9]. The overexpression of antiapoptotic and other cell pro-
liferation factors, together with point-mutations in abl-domain
[10,11], can be responsible for development of resistance to
the conventional anti-bcr-abl drugs after their long-term
application.
The discovery of RNA interference (RNAi) mechanism in
mammalian cells in 2001 [12,13] enhanced the expectations to
decide the problems of gene therapy of bcr-abl abnormality.
The eﬀorts were directed to the application of this natural
phenomenon for a speciﬁc inﬂuence of oncogene and onco-
protein expression.
RNAi is conserved in a diverse variety of simpler organisms
(such as nematodes, plants and Drosophila) [14–16]. RNAi is
mediated by siRNAs that are produced from long dsRNAs of
exogenous or endogenous origin by an endonuclease of the
ribonuclease-III type, called Dicer. The resulting siRNAs are
about 21–23 nucleotides long and these short fragments serve
as guide sequences to induce target-speciﬁc mRNA cleavage by
the RNA-induced silencing complex [17–19]. This mechanism
is extremely potent and requires only a few dsRNA molecules
per cell to silence homologous gene mRNA expression.ation of European Biochemical Societies.
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gene knockdown experiments and ultimately for therapeutic
purposes because siRNA-mediated transcriptional silencing is
highly gene-speciﬁc and without secondary eﬀects. However,
caution is needed because of the ﬁndings that some siRNAs
induce interferon-stimulated genes in mammalian cells in vitro
[20]. Moreover, it is too early to say how great is the promise of
RNAi because of many queries to the estimation of real
eﬃcacy of siRNAs, as their extremely diﬃcult intracellular
delivery without transfectants, transient nature of RNAi, side-
eﬀects during long-term treatment, etc.
The present study was designed to compare the eﬀects of two
independent pathways for bcr-abl suppression (siRNA-medi-
ated inhibition of bcr-abl protein synthesis and Glivec-medi-
ated inhibition of tyrosine kinase activity of already
synthesized bcr-abl protein) on the cross-expression of other
oncogenes, apoptotic/antiapoptotic genes and cell prolifera-
tion factors that can be responsible for restoration of cell im-
mortalization and development of drug resistance.2. Materials and methods
2.1. siRNAs
Twenty one nucleotide ds/siRNAs were chemically synthesized
(Genenet Co. Ltd., Fukuoka, Japan). They were directed to human
bcr-abl fusion peptide (major breakpoint, abl gene). The sense cDNA
sequence was in exon 548  843 (number 3, abl gene) – for siRNA-1
and siRNA-3; and in exon 374  547 (number 2, abl gene) – for siR-
NA-2 (GenBank Accession No. AJ131466.1 and X16416.1). The sense
mRNA/cDNA target sequences and antisense siRNA sequences are
shown in Fig. 1A. The following mismatch ds/siRNA (non-sense) was
used as a negative control: siRNA-4 – r(GUUUGUCAGAGU
CGGACAG)d(TT)/r(CUGUCCGACUCUGACAAAC)d(TT).
2.2. Cells and siRNA transfection protocol
Bcr-abl positive K-562 cells (derived from CML patients in blast
crisis) were a generous gift of Dr. J. Minowada (Hayashibara Bio-
chemical Laboratories, Inc., Okayama, Japan). The cells were cultured
in RPMI-1640 medium, supplemented with 10% heat-inactivated fetal
bovine serum in a humidiﬁed atmosphere at 37 C with 5% CO2. The
cells used for transfection were about 80% conﬂuenced. The cells used
for assay were in a logarithmic phase.
Normal lymphocytes were puriﬁed from heparinized peripheral
blood obtained from normal adults (aged 40–42 years) by Lym-
phosepar I.
All cells were sedimented by centrifugation (1000 rpm, 10 min) and
washed three times by PBS()) before experiments.
Transfection conditions: collection of cells by centrifugation, re-
suspendation of cells in a new medium to 8 105 cells/ml, transfection
of siRNAs (mix of the three sequences – 3 60 nM) using lipofecta-
mine (6 h incubation in RPMI-1640 medium in the presence of 10 U/ml
RNase inhibitor (Roche)), replacement of cells in a new medium
(4 105 cells/ml) and cultivation in a humidiﬁed atmosphere. The
conditions for preparation of ds/siRNA–lipofectamine complexes are
described in Lipofectamine’2000 protocol (Invitrogen). Transfection
eﬃcacy was analyzed using lamin A/C system (RNAi Started kit,
Qiagen). Three repetitive transfections were applied as shown in
Fig. 1C.
The half-life of ds/siRNAs in RPMI-1640 medium during transfec-
tion was analyzed by gel electrophoresis (using UV-detection) and
HPLC (using ﬂuorescein-labeled ds/siRNA and ﬂuorimetric detection).
2.3. Confocal microscopy – ds/siRNAs cellular uptake
Cells (2 105 cells/ml) were transfected with ﬂuorescein-labeled ds/
siRNA (single dose 180 nM, Qiagene) using lipofectamine as described
above. Six hours transient transfection was applied and transfected
cells were cultured in RPMI-1640 medium. At diﬀerent times of post-
transfection (1, 2, 4, 6 and 8 h), aliquots of the cells were sedimented by
centrifugation (1000 g/10 min), washed twice with PBS (Ca2þ andMg2þ free) to eliminate free ﬂuorescent ds/siRNA molecules outside
the cells, and the FITC-labeled ds/siRNA, incorporated into the living
cells (green light), were detected by ﬂuorescent confocal microscopy.
The samples were analyzed by Olympus IX70 microscope.
2.4. Treatment with Glivec
Glivec was kindly provided by Novartis (Novartis, Switzerland). It
was applied to the cells in a concentration of 180 nM every two days
(the protocol is similar to that in Fig. 1C) during 8 days to obtain
analogous to siRNA-protocol reduction of cell proliferation.
2.5. mRNA isolation
mRNA was isolated from ds/siRNA- or Glivec-treated and -un-
treated cells, using QuickPrep mRNA Puriﬁcation kit (Amersham
Pharmacia), as described in the manufacturer’s protocol. Brieﬂy, total
RNA was extracted in a buﬀered solution containing a high concen-
tration of GTC and N-lauroyl sarcosine, which ensured the rapid in-
activation of endogenous RNase and the complete dissociation of
cellular components from the mRNA. The extracts were then diluted
threefold with elution buﬀer (10 mM Tris–HCl, pH 7.5 and 1 mM
EDTA) to reduce the GTC concentration to a level enough to allow
eﬃcient hydrogen-bonding between poly(A) tracts on mRNA mole-
cules and oligo(dT) attached to cellulose, but high enough to maintain
complete inhibition of RNases. Threefold dilution also caused pre-
cipitation of some proteins, which were removed by centrifugation
(12 000 g for 10 min). The supernatant was poured into an oligo(dT)-
cellulose spun column and polyadenylated fraction was allowed to
bind over a short period of time with gentle mixing (10 min). The
column was subjected to a low-speed centrifugation (350 g for 2 min)
and the liquid, containing the non-bound material, was decanted. The
matrix was batch-washed sequentially with high-salt (10 mM Tris–
HCl, pH 7.5, 1 mM EDTA and 0.5 M NaCl) and then low-salt buﬀer.
Finally, the sample was eluted from the matrix prewarmed at 65 C
with elution buﬀer (10 mM Tris–HCl, pH 7.5 and 1 mM EDTA).
Precipitation of mRNA from eluate (0.5 ml) was carried out by
potassium acetate solution (50 ll–5 M, pH 5.0), glycogen solution
(10 ll–20 mg/ml in DEPC-treated water) and 95% ethanol (1 ml) for 30
min at )20 C. The precipitated mRNA was resuspended in DEPC-
treated water and its concentration was determined spectrophoto-
metrically at 280 nm. The mRNA isolated was essentially free of DNA
and protein contamination. Aliquots of mRNA in equal concentration
were applied for reverse transcription-polymerase chain reaction (RT-
PCR) analysis.
2.6. RT-PCR
RT-PCR was performed by OneStep RT-PCR kit (Qiagene) in ac-
cordance to the manufacturer’s instructions. The following gene-spe-
ciﬁc primers were used: abl-FP (24-mer), 50-CTC ATA TCA ACC
CGA GTG TCT CTT-30; abl-RP (24-mer), 50-TGC TAC CTC TGC
ACT ATG TCC ATG-30; bcr-abl fusion-FP (26-mer), 50-GAA GAA
GTG TTT CAG AAG CTT CTC CC-30; bcr-abl fusion-RP (25-mer),
50-GAC CCG GAG CTT TTC ACC TTT AGT T-30. The reverse-
transcription reaction was carried out at 50 C for 30 min, followed by
HotStar Taq DNA polymerase activation by heating at 95 C for
15 min. Three-step cycling was performed: denaturation – 1 min at 94
C, annealing – 1 min at 50–68 C, and extension – 1 min at 72 C. The
number of cycles was 40, followed by ﬁnal extension at 72 C for
10 min. cDNA (RT-PCR product) was dissolved in loading buﬀer and
was analyzed by electrophoresis on 1% agarose precast gel with ethi-
dium bromide (100 V, 30–40 min, at room temperature, RT 22 C).
To ensure that there are no artifacts in our RT-PCR procedure, we
analyzed also the expression levels of housekeeper b-actin mRNA in
each sample as endogenous reference, using commercially available
primers (Qnet).
2.7. Western blot analysis of p210 bcr-abl protein
The cells were treated with ds/siRNAs or Glivec as described above.
Aliquots of 4 105 cells were lysed in TeloChaser buﬀer (containing
protease and phosphatase inhibitor cocktail, Toyobo Co. Ltd.) for
30 min at 4 C, centrifuged at 12 000 g/20 min/4 C and the super-
natant was dissolved 1:1 in 2 Laemmli sample buﬀer (1.1 M Tris–
HCl, pH 6.0, 3.3% SDS, 22% glycerol, 10% b-mercaptoethanol and
0.001% bromophenol blue). Samples (in equal protein concentration)
were heated at 95 C for 10 min and were applied to 5% stacking,
4–12% resolving SDS–polyacrylamide gel. Electrophoresis was
Fig. 1. (A) Sequences of chemically synthesized anti-bcr-abl ds/siRNAs and their sense mRNA/cDNA target sequences. TT indicates the deoxy-
thymidine dimer as 30 overhang. (B) Intracellular uptake of ds/siRNAs. Cells (2 105 cells/ml) was transfected during 6 h with ﬂuorescein-labeled ds/
siRNA using lipofectamine as described in Section 2. The cells were sedimented by centrifugation, washed twice with PBS (Ca2þ and Mg2þ free), and
the ﬂuorescein-labeled ds/siRNA, incorporated into the living cells (green light), were detected by ﬂuorescent confocal microscope. (C) Scheme of
‘‘chronic treatment’’ of cells with ds/siRNA-mix or ds/siRNA-non-sense. ds/siRNA-mix consisted of three ds/siRNAs (3 60 nM).
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BioRad Kaleidoskop protein standards were also applied for com-
parison. After electrophoresis, the separated protein fractions were
transferred to a Hybond-P PVDF membrane (Amersham Bioscience),
using XCell II Blot Module (Novex). The transfer was carried out at
35 V for 18 h at 4 C. The membranes were cut at 45 kDa (for b-actin)
and 210 kDa (for bcr-abl) molecular weight levels. A double antibody
procedure was used to detect the proteins. The membranes were in-
cubated under agitation for 1 h at RT in a blocking solution (PBS,
containing 5% dry skimed milk and 0.1% Tween 20), then at RT for 1 h
in anti-c-abl (rabbit, Sigma; 1:100 dilution for bcr-abl detection) or
anti-b-actin monoclonal antibodies (mouse, Calbiochem; 1:20 000).
The antibody solution was removed and the membranes were washed
three times with PBS, containing 0.1% Tween 20. The membranes were
then incubated (1 h at RT under agitation) with horseradish peroxi-
dase-conjugated goat anti-rabbit IgG (Sigma, 1:5000) for anti-c-abl
and goat anti-mouse IgM (Sigma, 1:2000) for anti-b-actin antibody.
Chemiluminescence was detected immediately using ECL Advance
Western Blotting Detection Kit (Amersham Bioscience).
2.8. Flow cytometry
Anti-c-abl antibody (rabbit, Sigma) was labeled by ZenonAlexa
Fluor-488 Rabbit IgG Labeling Kit (Molecular Probes). Permeabili-
zation of cells (treated or non-treated with ds/siRNA or Glivec) for
Fluor-488-conjugated anti-c-abl antibody was carried out by IntraPrep
Permeabilization Reagent (Immunotech). The antibody–antigene in-
teraction was detected by ﬂow cytometry (Beckman Coulter-Epics
XL). Data were collected and analyzed by ‘‘XL System II software’’.
No cells were excluded from the analysis and 5000 cells were coun-
ted. The results were presented as a dot plot of Fluor-488 ﬂuorescence
(side scatter, SS – y-axis in 0–128 scale, vs. Fluor-488-conjugated an-
tibody, Fluor-488 – x-axis in 1–1000 scale) with quadrant markers
drawn to distinguish the cells, containing diﬀerent levels of antibody–
antigene complexes.
2.9. Tyrosine kinase activity test
The cells (treated or non-treated with ds/siRNA or Glivec) were
sedimented by centrifugation (1000 g/10 min), washed twice with PBS
(Ca2þ and Mg2þ free) and re-suspended in lysis buﬀer (TeloChaser,
Toyobo Co., Ltd.). The lysis was carried out at 4 C for 30 min in the
presence of orthovanadate. The cytosolic fraction, containing bcr-abl,
was obtained after centrifugation at 12 000 g/10 min, 4 C. Bcr-abl
oncoprotein was isolated together with c-abl (p150) by immunopre-
cipitation, using anti-c-abl antibody (Sigma, 3 lg/ml) and protein A/G
agarose beads. The tyrosine kinase activity of immunoprecipitated en-
zymes was analyzed, using CHEMICON’s PTK Assay kit (with slight
modiﬁcations). In brieﬂy, a synthetic biotinylated poly[Glu:Tyr], 4:1
(2.5 lg/ml), containing multiple tyrosine residues, was used as a PTK
substrate. The PTK reaction was started in cell lysate by 1 mMATP/10
mMMgCl2 and continued 60 min at 37 C. After quenching the enzyme
reaction with an inhibitor (100 mM EDTA), both the phosphorylated
and dephosphorylated substrates were immobilized to the streptavidin-
coated 96-well plates. The fraction of phosphorylated substrate was
visualized spectrophotometrically at 450 nm, using HRP-conjugated
mouse anti-phosphotyrosine antibody (clone PY20) and an ensuing
chromagenic substrate reaction. The quantity of phosphate, incorpo-
rated into the tyrosine kinase substrate, was determined utilizing the
phosphopeptide standard curve.
2.10. Cell proliferation test
Cells (2 105 cells/ml) were cultured in the presence or in the ab-
sence of ds/siRNAs or Glivec, as described above. The cell growth was
detected spectrophotometrically, using CellTiter AQ Proliferation
Assay Kit (Promega). The method is based on the detection of the
number of viable cells in proliferation. A tetrazolium compound
(MTS) is bioreduced by cells into a formazan product in the presence
of an electron coupling reagent (phenazine methosulfatef), based on
the method of Mosmann [21]. The absorbance of formazan product at
490 nm (OD490 nm) was recorded using 96-well plate reader Inter-
MedImmunomini NJ-2300 (InterMed, Japan).2.11. Cell viability assay of normal lymphocytes
The viability of siRNA- and Glivec-treated normal lymphocytes was
measured by CellTiter-GloTM luminescent cell viability assay. ATPbioluminescence was used as a marker of cell viability. Brieﬂy, the cells
(siRNA/Glivec-treated or untreated) were suspended in the culture
medium to a concentration of 5 105 cells/ml and then were added in
90 ll aliquots to 96-well plates. CellTiter 96 kit (Promega) was added
in aliquots of 90 ll to each patch and incubated with cell suspensions
for 1 h, following the procedure recommended by the producer. The
luminescence, produced by luciferase-catalyzed luciferin+ATP reac-
tion, was measured by MicroLumat LB96P (Perkin–Elmer). The data
were normalized to the control group (consisted of untreated cells).
Cell viability of siRNA/Glivec-treated cells was calculated as % of
luminescence in comparison with the control.
2.12. Microarray analysis
The RT labeling and hybridization followed the protocol recom-
mended by Agilent Technologies Inc. intended for Agilent microarray
analysis. Brieﬂy, a 20-lg aliquot of each mRNA sample was reverse
transcribed into a cDNA probe with oligo(dT) primer and labeled
nucleotides. The reaction was carried out in a solution containing
50 lM dATP/dGTP/dTTP, 25 lM dCTP, 25 lM cyanine 3 (Cy3)-
dCTP (for control non-treated sample) or cyanine 5 (Cy5)-dCTP (for
ds/siRNA-mix- or Glivec-treated sample) (Enzo Diagnostics, Inc.) and
400 U MMLV reverse transcriptase at 42 C for 1 h. The labeling
reaction was terminated by incubating the reaction mixture at 70 C
for 10 min. The RNA was then degraded by adding 0.05 lg RNaseIA,
followed by incubation at 37 C for 30 min. Degraded RNA and un-
incorporated nucleotides were removed using a QIAquick PCR Puri-
ﬁcation Kit (Qiagen Inc.) according to the instructions of Agilent
Technologies Inc. Hybridization was carried out in 22 ll of a hy-
bridization mixture containing cDNA probes, the labeled orientation
marker (Deposition Control SP300; Operon Technologies Inc.) and
mouse Cot-1 DNA (Invitrogen Corporation) at 65 C for 17 h. The
glass slides were then washed with 0.5 SSC and 0.01% SDS at RT for
5 min, and with 0.06 SSC at room temperature for 2 min. After
immediately removing the wash buﬀer by centrifugation, the glass
slides were scanned using GenePix 4000B (Axon Instruments, Inc.)
containing a 532 nm laser for Cy3 measurement and a 635 nm laser for
Cy5 measurement. Scans were made with a pixel resolution of 5 lm, a
laser power of 100%, and a photomultiplier tube voltage of 600 V for
the 532 nm laser and 520 V for the 635 nm laser.
To eliminate the eﬀect of lipofectamine on the gene proﬁle of K-562
cells, in siRNA protocol control cells consist of cells treated with
lipofectamine only on the scheme, shown in Fig. 1C.
Normalization and analysis of microarray data. Sixteen-bit TIFF
images produced by the Axon scanner were analyzed using the
GenePixPro 3.0 (Axon Instruments, Inc.) software package. After
obtaining Cy3 and Cy5 grayscale images, each pseudo-color image was
overlaid, and all spots in the ratio image were deﬁned by accessing the
gene list ﬁle that described the location of each gene on the microarray.
The average of the signal intensity was subtracted from the median of
background intensity and outputted with the UniGene and GenBank
descriptors to a Microsoft Excel data spreadsheet. Relative expression
levels were calculated by global normalization between two samples
using all detected genes, after the exclusion of spots annotated as
‘‘Agilent QC’’, ‘‘Agilent Blank’’, and ‘‘Buﬀer’’.
2.13. Statistical analysis
One-way analysis of variance was employed, followed by Bonfer-
roni’s test for truly signiﬁcant diﬀerences. Statistical signiﬁcance was
deﬁned at P < 0:05. The statistical procedures were performed with
GraphPad InStat software, version 2.04, USA. Data are expressed as
mean S.D.3. Results and discussion
The sequences of the originally designed and chemically
synthesized ds/siRNAs are shown in Fig. 1A. The DNA target
sequences were localized in the abl-part of bcr-abl major
breakpoint of Philadelphia chromosome, which is character-
ized by a bcr exon 3/abl exon 2 (b3a2) junction (an unique
sequence in K-562 cells). The selection of DNA target se-
quences aimed to avoid the most sensitive for point mutations
area in abl-part of bcr-abl gene (around Tyr315), responsible for
Fig. 2. (A) Eﬀect of ds/siRNA-mix on the bcr-abl mRNA in K-562 cells. The cells were transfected with ds/siRNA-mix (3 60 nM) or ds/siRNA-
non-sense (180 nM) as described in Section 2. Cell lysates were obtained after 6 days treatment and mRNA was isolated. The synthesis of bcr-abl
cDNA was carried out by RT-PCR and the product was analyzed by TBA-electrophoresis on 1% agarose precast gel with ethidium bromide. Blots
from one typical experiment are shown in the ﬁgure. In the histograms, the results are expressed as bcr-abl cDNA/b-actin cDNA and were given as a
percentage from the control group. The value of bcr-abl cDNA/b-actin cDNA in control (cells treated with lipofectamine only) was considered as
100%. The data are means S.D. from six independent experiments. *** P < 0:001 vs. control group. (B) Eﬀect of ds/siRNA-mix on the level of bcr-
abl oncoprotein in K-562 cells – Western blot analysis. The cells were treated with ds/siRNA-mix (3 60 nM) or ds/siRNA-non-sense (180 nM) and
cell lysates were obtained after 6 days treatment as described in Section 2. The samples (in equal protein concentration) were dissolved 1:1 in 2
Laemmli buﬀer, heated at 95 C for 10 min and subjected to SDS–polyacrylamide gel electrophoresis (80 V, 15 min; 120 V, 2 h at RT). The separated
protein fractions were transferred to a Hybond-P PVDF membrane overnight at 35 V (4 C). The membranes were cut at 45 kDa (for b-actin) and
210 kDa (for bcr-abl) and were incubated as follows: 1 h at RT in a blocking solution, 1 h in anti-c-abl antibody (rabbit, Sigma, 1:100 for detection of
bcr-abl) or in anti-b-actin antibody (mouse, Calbiochem, 1:20 000), 1 h with HRP-conjugated goat anti-rabbit IgG (Sigma, 1:5000) for anti-c-abl or
goat anti-mouse IgM (Sigma, 1:2000) for anti-b-actin. Chemiluminescence was detected immediately using ECL Advance Western Blotting Detection
kit (Amersham Bioscience). Blots from one typical experiment are shown in the ﬁgure. Control blots are representative for cells treated with
lipofectamine only. In the histograms, the results are expressed as a percentage from the control group. The value of p210 bcr-abl protein in control
(cells treated with lipofectamine only) was considered as 100%. The data are means S.D. from ﬁve independent experiments. ** P < 0:01 vs control
group. (C) Eﬀect of ds/siRNA-mix on the protein tyrosine kinase activity in K-562 cells. The cells were treated with ds/siRNA-mix (3 60 nM) or ds/
siRNA-non-sense (180 nM) as described in Section 2 and cell lysates were obtained after 6 days treatment. Bcr-abl p210 oncoprotein was isolated
together with c-abl p150 by immunoprecipitation, using anti-c-abl antibody (Sigma, 3 lg/ml) and protein A/G agarose beads. The tyrosine kinase
activity of immunoprecipitated enzymes was analyzed, using CHEMICON’s PTK Assay kit. The fraction of phosphorylated substrate was visualized
spectrophotometrically at 450 nm, using HRP-conjugated anti-phosphotyrosine antibody (clone PY20) and ensuing chromagenic substrate reaction.
The data are presented as meansS.D. from ﬁve independent experiments. OD450 nm ¼ 1.0 corresponds to 20 ng P-Tyr-peptide substrate. The
calibration curve was linear in the range 10–40 ng P-Tyr-peptide substrate. Control groups are representative for cells treated with lipofectamine
only. ** P < 0:01 vs. control group. (D) Eﬀect of ds/siRNA-mix on the cell proliferation activity of K-562 cells. The cells were cultured in the
presence or in the absence of ds/siRNA-mix (3 60 nM) or ds/siRNA-non-sense (180 nM) as described in Section 2. The cell proliferation activity
was detected spectrophotometrically, based on the reduction of MTS into a formazan product (absorbance at 490 nm). The data were calculated as a
percentage from control (cells, treated with lipofectamine only). The cell proliferating activity of control cells was considered as 100%. The results are
presented as means S.D. from eight independent experiments. ** P < 0:01 vs. control group.
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ing long-term treatment with conventional antileukemia drugs
(as it has been described in the clinical trials with Glivec [10,11])
(Fig. 1A). Thus, the designed ds/siRNAs have a potential to
express their activity if they are applied in combination with
Glivec during long-term treatment of bcr-abl-positive cells.
Several commercially available liposomal transfection re-
agents (Lipofectamine 2000 from Invitrogen, Superfect and
Lipofect from Qiagen) were tested for their ability to deliver
ds/siRNAs into bcr-abl-positive K-562 cells, as well as to
preserve ds/siRNAs against degradation in RPMI-1640 me-
dium. K-562 cells were found to be suitable for analysis be-
cause they contained a functional RNA interference
mechanism to bind to siRNAs and to mediate mRNA degra-
dation, which was conﬁrmed in preliminary experiments by
lamin A/C system (RNAi Starter kit, Qiagen, and anti-lamin
A/C antibody – Chemicon). Transfection eﬃcacy was also
analyzed using lamin A/C system. The preference was given to
lipofectamine because of most optimal conditions for com-
paratively high cellular uptake (transfection eﬃcacy reached
approximately 70% in K-562 cells, data not shown) and long
half-life of ds/siRNA sequences during transfection. The half-
life of ﬂuorescein-labeled ds/siRNA–lipofectamine complexes
in cell culture medium was 10 h, determined by HPLC. The
selection of ds/siRNA/lipofectamine ratio meant to avoid also
side-eﬀects of lipofectamine on cell viability and proliferation.
No signiﬁcant changes were detected in the viability and pro-
liferation activity of leukemia cells, treated during 6 h with
lipofectamine alone or in combination with ds/siRNAs (data
are not shown). The cells, treated with lipofectamine only,
were used as controls. It was established that only 20% of ds/
siRNAs degradated during 6 h incubation in the medium if the
siRNA sequences are in a complex with lipofectamine.
The time-dependent cellular uptake of ds/siRNAs was de-
tected by ﬂuorescent confocal microscopy, using ﬂuorescein-
labeled ds/siRNA (Fig. 1B, green light). A comparatively good
intracellular uptake of ds/siRNA was detected on the 6th hour
of the beginning of transfection. In contrast, ds/siRNA was
not detected in the cells without any lipofectamine (no ﬂuo-
rescence was observed in the cells). Based on the preliminary
experiments, 6 h transient transfection of ds/siRNAs using
lipofectamine was applied and the transfected cells were re-
placed in a new culture medium.
Bcr-abl protein is considered as ‘‘a protein – relatively stable
to the antisense attack’’ and it is diﬃcult to inﬂuence its level
by single and short-term application of anti-bcr-abl sub-
stances. In our previous work, we demonstrated that relatively
long-term ‘‘chronic’’ application (6 days and more) of anti-bcr-
abl oligo-DNAs markedly reduced the level of bcr-abl proteins
and inﬂuenced signiﬁcantly the proliferation activity of K-562
[8,9]. In this context, anti-bcr-abl ds/siRNAs have also a po-
tential to manifest cytotoxicity and to suppress the prolifera-
tion during long-term treatment, as it has been assumed by
other authors [5,6]. To guarantee enough time for induction of
mRNA cleavage as well as for re-synthesis of the target on-
coproteins, ‘‘chronic treatment’’ of K-562 cells with ds/siRNAs
(mix of the three sequences in equal concentrations – 3 60
nM) was applied. The scheme of ‘‘chronic treatment’’ is shown
in Fig. 1C. It includes three repetitive transfections of ds/siR-
NA-mix (every two days) and the eﬀects on bcr-abl mRNA,
p210 and all other parameters were analyzed on the 6th day.
The major problem in this experimental protocol was tominimize the side-eﬀects of lipofectamine during repetitive
transfections and it was established that the selected scheme
overcame this restriction. No signiﬁcant changes in parameters
analyzed were detected in K-562 cells, treated with lipofecta-
mine only as shown in Fig. 1C.
The capacity of ds/siRNA-mix to reduce the amount of bcr-
abl mRNA in K-562 cells was estimated by RT-PCR (Fig. 2A).
The treatment of cells with ds/siRNA-mix markedly reduced
(82%) the level of bcr-abl mRNA. Similar eﬀect was obtained
on the level of p210 bcr-abl oncoprotein, determined by im-
munoblot analysis (64% reduction was detected, Fig. 2B). ds/
siRNAs-treatment of K-562 cells provoked also a signiﬁcant
decrease of their bcr-abl/c-abl tyrosine kinase activity (57%,
Fig. 2C) and cell proliferation capacity (50%, Fig. 2D).
Mismatch-ds/siRNA did not inﬂuence the parameters ana-
lyzed, indicating the sequence speciﬁcity of ds/siRNA-mix.
Obviously, the ‘‘chronic treatment’’ can overcome the tran-
sient nature of RNAi and to guarantee comparatively strong
suppression of bcr-abl mRNA and oncoprotein expression.
Since the selected ds/siRNAs have a potential to target also
c-abl mRNA (Fig. 1A) and to inﬂuence the homeostasis of
normal cells, we clariﬁed the eﬀect of ds/siRNA-mix
(3 60 nM) on the viability of normal lymphocytes after
‘‘chronic treatment’’. It was observed that ds/siRNA-mix did
not express cytotoxicity to normal lymphocytes, at least during
6 days treatment on the scheme, as shown in Fig. 1C. This
result does not exclude an expression of cytotoxicity of the
designed ds/siRNAs to normal cells during long-term treat-
ment and the sequences targeted only to fusion part of bcr-abl
mRNA have a privilege.
The eﬃciency of the designed ds/siRNAs was compared with
that of Glivec. Glivec was applied in a dose of 180 nM every two
days (as shown in Fig. 1C). To guarantee an equal eﬀect of ds/
siRNA-mix and Glivec on the cell proliferation activity of K-
562 cells, the treatment with Glivec was carried out every two
days and the eﬀects on the parameters analyzedwere detected on
the 8th day. The results in Fig. 3 demonstrate that Glivec de-
creased markedly protein tyrosine kinase activity (73%) and
cell proliferation capacity (54%), and provoked a compara-
tively poor decrease of bcr-abl protein (14%).
Recently, we demonstrated that relatively long-term
‘‘chronic’’ application (6 days and more) of anti-bcr-abl oligo-
DNAs markedly reduced the level of bcr-abl protein, but their
sequence-speciﬁc eﬀect was accompanied with inﬂuence of
telomeric-associated proteins, increased telomerase activity
and restoration of cell proliferation capacity in the treated cells
[8,9]. Therefore, the comparatively long-term siRNA interfer-
ence of bcr-abl oncogene has also a potential to inﬂuence
positively the expression of other oncogenes, as well as factors,
responsible for the proliferation and immortalization of bcr-
abl-positive cells.
Similar eﬀects have also been reported for Glivec. Brum-
mendorf et al. [22] found an extension of the telomeres in
CML-patients after long-term treatment with Glivec in both
chronic phase and blast crisis. Analyzing 517 samples from 206
patients, the authors have been established that telomere
length from start of treatment up to day 144 is signiﬁcantly
shorter compared with patients treated for more than 144
days. In patients with repeated measurements, a signiﬁcant
increase in telomere length under treatment is observed. Me-
dian telomere length in major remission has been found to be
signiﬁcantly longer in comparison with patients without
Fig. 3. (A) Eﬀect of Glivec on the level of bcr-abl oncoprotein in K-562 cells – Western blot analysis. The cells were treated with Glivec and cell
lysates were obtained after 8 days treatment as described in Section 2. The samples (in equal protein concentration) were dissolved 1:1 in 2 Laemmli
buﬀer, heated at 95 C for 10 min and subjected to SDS–polyacrylamide gel electrophoresis (80 V, 15 min; 120 V, 2 h at RT). The separated protein
fractions were transferred to a Hybond-P PVDF membrane overnight at 35 V (4 C). The membranes were cut at 45 kDa (for b-actin) and 210 kDa
(for bcr-abl) and were incubated as follows: 1 h at RT in a blocking solution, 1 h in anti-c-abl antibody (rabbit, Sigma, 1:100 for detection of bcr-abl)
or in anti-b-actin antibody (mouse, Calbiochem, 1:20 000), 1 h with HRP-conjugated goat anti-rabbit IgG (Sigma, 1:5000) for anti-c-abl or goat anti-
mouse IgM (Sigma, 1:2000) for anti-b-actin. Chemiluminescence was detected immediately using ECL Advance Western Blotting Detection kit
(Amersham Bioscience). Blots from one typical experiment for each protein are shown in the ﬁgure. Control blots are representative for untreated
cells. In the histograms, the results are expressed as a percentage from the control group. The value of p210 bcr-abl protein in control was considered
as 100%. The data are meansS.D. from four independent experiments. * P < 0:05 vs. control group. (B) Eﬀect of Glivec on the level of bcr-abl
oncoprotein in K-562 cells – ﬂow cytometric analysis. The cells were treated with Glivec as described in Section 2. After 8 days treatment, the cells
were analyzed for the level of bcr-abl oncoprotein. Anti-c-abl antibody (rabbit, Sigma) was labeled by ZenonAlexa Fluor-488 Rabbit IgG Labeling
kit (Molecular Probes). Permeabilization of cells for the Fluor-488-conjugated anti-c-abl was carried out by IntraPrep Permeabilization Reagent
(Immunothech). The antibody–antigene interaction was detected by ﬂow cytometry. Data are presented as a dot plot of Fluor-488 ﬂuorescence (side
scatter, SS – y-axis, vs. Fluor-488-conjugated antibody – x-axis in 1–1000 scale) with quadrant markers drawn to distinguish the cells, containing
diﬀerent levels of antibody–antigene complexes. In the histograms, quadrant H corresponds to the cells, containing maximum level of bcr-abl
(positive control), quadrant G corresponds to the cells without ﬂuorescent marker and therefore without bcr-abl–antibody complexes (spontaneous
cell ﬂuorescence, negative control), and the section between H and G (mentioned as E) corresponds to the cells, containing moderate or low level of
Fluor-488-conjugated c-abl antibody and therefore expressing moderate or low levels of bcr-abl oncoprotein in comparison with the positive control.
Histograms from one typical experiment are shown in the ﬁgure. Positive control is representative for Glivec-untreated cells. (C) Eﬀect of Glivec on
the protein tyrosine kinase activity in K-562 cells. The cells were treated with Glivec as described in Section 2 and cell lysates were obtained after 8
days treatment. Bcr-abl oncoprotein was isolated together with c-abl by immunoprecipitation, using anti-c-abl antibody (Sigma, 3 lg/ml) and protein
A/G agarose beads. The tyrosine kinase activity of immunoprecipitated enzymes was analyzed, using CHEMICON’s PTK Assay kit. The fraction of
phosphorylated substrate was visualized spectrophotometrically at 450 nm, using HRP-conjugated anti-phosphotyrosine antibody (clone PY20) and
ensuing chromagenic substrate reaction. The data are presented as meansS.D. from six independent experiments. OD450 nm ¼ 1.0 corresponds to
20 ng P-Tyr-peptide substrate. The calibration curve was linear in the range 10–40 ng P-Tyr-peptide substrate. *** P < 0:001 vs. control group. (D)
Eﬀect of Glivec on the cell proliferation activity of K-562 cells. The cells were cultured in the presence or in the absence of Glivec as it was described
in Section 2. The cell proliferation activity was detected spectrophotometrically after 8 days treatment, based on the reduction of MTS into a
formazan product (absorbance at 490 nm). The data were calculated as a percentage from control non-treated cells. The cell proliferating activity of
control cells was considered as 100%. The results are presented as meansS.D. from eight independent experiments. ** P < 0:01 vs. control group.
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phase FISH, or quantitative RT-PCR.
Obviously, both pathways of bcr-abl suppression – siRNA-
mediated cleavage of bcr-abl mRNA and Glivec-mediated
inhibition of already synthesized fusion protein, are in a cross-
talk with other oncogenes, apoptotic/antiapoptotic and cell
proliferation factors. Both mechanisms keep a potential for
restoration of the proliferation and immortalization of leuke-Table 1
Transcripts of interest suppressed >3 times in siRNA- or Glivec-treated K-5
Accession number Description
Factors, responsible for cell proliferation and immortalization
U47077 Human DNA-dependent protein kinase catalytic subun
M23102 Human trk proto-oncogene insert of pLM6
U51869 Human proto-oncogene Bcd orf1 and orf2 mRNA
AF152961 Human chromatin-speciﬁc transcription elongation fact
140 kDa subunit mRNA
AJ000052 Human gene encoding splicing factor SF1, exons 2–8
D29767 Human mRNA for Tec protein tyrosine kinase
X07109 Human mRNA for protein-kinase C-beta II
D51465 Nuclear factor I/X (CCAAT-binding transcription fact
NM_00325 Tight junction protein 1
AF017789 Human putative transcription factor CA150 mRNA
T36282 Guanylate kinase
M54968 Human k-ras oncogene protein mRNA
L23320 Human replication factor C large subunit mRNA
S49592 E2F transcription factor
M34057 Latent transforming growth factor beta binding protein
AU118354 ATP-binding cassette, sub-family G (WHITE), member
M32721 Hyman poly(ADP-ribose)-polymerase mRNA
M64347 Human novel growth factor receptor mRNA
AB005659 ATP-binding cassette, sub-family C (CFTR/MRP), me
Factors, responsible for apoptosis induction
AF249273 Human Bcl-2-associated transcription factor
BI545796 Protein phosphatase 2, regulatory subunit B
Y13247 Protein phosphatase 1, regulatory subunit 10
U03106 Human wild-type p53 activated fragment-1
AB002331 Death-associated transcription factor 1
NM_03334 Caspase-7, apoptosis-related cysteine protease
Table 2
Transcripts of interest overexpressed >3 times in siRNA- or Glivec-treated
Accession number Description
Factors, responsible for cell proliferation and immortalization
M24779 Human protein kinase-related oncogene (PIM1
AA232339 Pim-1 oncogene
AA863383 Pim-2 oncogene
BM020481 Tumor protein D52-like 1
J04111 Human c-jun proto oncogene, clone hCJ-1
X52125 Human alternatively spliced c-myb mRNA, clo
X52479/AF035594 Protein-kinase C-alpha mRNA for PK-C-alpha
AI498125 Pvt-1 oncogene homolog, MYC activator
U80017 Human basic transcription factor 2 p44 (MAP
BG387620 v-myb myeloblastosis viral oncogene homolog
M96956 Teratocarcinoma-derived growth factor, clone
AF053949 Human transcription factor CBFA1/OSF2 gen
X52125 Human alternatively spliced c-myb mRNA
Factors, responsible for apoptosis induction
M54894 Interleukin-6 (interferon, beta 2)
X57351 Human 1-8D gene from interferon-inducible ge
AA769631 Tumor necrosis factor receptor superfamily, 10
AF090693 Human apoptosis-related RNA binding protein
J04164 Human interferon-inducible protein 9-27
BC010399 STAT induced STAT inhibitor-2
NM00218 Interleukin-13mia cells. To verify the factors potentially responsible for side-
eﬀects of Glivec and bcr-abl RNAi during long-term treatment,
we provided amicroarray analysis of gene proﬁle in K-562 cells,
‘‘chronically’’ treated with ds/siRNA-mix or Glivec.
The expression of 162 and 104 genes was found to
decrease and increase (>3 times), respectively, in ds/siRNA-
treated cells versus 94 and 76 genes in Glivec-treated. The
data in Tables 1 and 2 summarize the signiﬁcant changes in62 cells – microarray analysis (P < 0:01)
siRNA-treated/
non-treated
Glivec-treated/
non-treated
it – 5.359
4.941 –
4.461 3.115
or FACT
4.371 3.903
3.982 3.234
3.859 3.594
– 3.634
or) 3.545 –
3.343 –
– 3.336
– 3.334
– 3.301
3.310 –
3.255 –
1 3.232 –
2 3.188 –
– 3.150
3.046 –
mber 5 3.015 –
4.501 3.044
– 4.453
– 4.111
4.310 –
3.241 –
3.109 –
K-562 cells – microarray analysis (p < 0:01)
siRNA-treated/
non-treated
Glivec-treated/
non-treated
) mRNA – 9.913
4.889 –
– 3.074
4.673 –
4.323 4.490
ne pMbm-1 – 4.496
4.171 3.134
4.104 3.881
K activator) – 3.565
3.452 –
CR-3 3.404 –
e 3.046 –
– 4.496
12.38 5.915
ne family 5.098 4.707
b 4.954 4.429
4.546 –
– 3.590
3.402 3.780
– 3.341
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cell proliferating factors and oncogenes. Table 1 includes the
transcripts with decreased expression in ds/siRNA- or Gli-
vec-treated K-562 cells (>3 times). RNAi of bcr-abl was
accompanied with decreased expression of several proto-
oncogenes (trk and Bcd orf1/orf2 proto-oncogenes), growth
factors (novel growth factor receptor, latent transforming
growth factor b binding protein 1), factors relating to kinase
activity (Tec protein tyrosine kinase, ATP-binding cassette –
sub-families C-CFTR/MRP and G-WHITE) and factors re-
lating directly to cell proliferation cycle (Table 1). Several
factors responsible for development of apoptosis also in-
creased signiﬁcantly (>3 times): STAT induced STAT
inhibitor-2, apoptosis-related RNA binding protein (NA-
POR-3), tumor necrosis factor receptor superfamily (member
10b), interleukin 6 (Table 2).
However, 6 days treatment of K-562 cells with anti-bcr-abl
ds/siRNA-mix resulted in a signiﬁcant decrease of several ap-
optotic factors (caspase-7, p53, death associated transcription
factor 1) and antiapoptotic factors (bcl-2-associated tran-
scription factor) (Table 1), as well as in a signiﬁcant increased
expression of the following transcripts that can be responsible
for restoration of the cell proliferation (Table 2): protein ki-
nase-related oncogene (PIM1), c-jun proto-oncogene, Pvt-1
oncogene homologue (myc-activator), protein kinase C-a gene,
teratocarcinoma-derived growth factor 3, transcription factor
CBFA1/OSF2.
Eight days treatment of K-562 cells with Glivec was ac-
companied with suppression of Bcd orf1/orf2 proto-oncogene,
k-ras oncogene, factors relating to kinase activity (Tec protein
tyrosine kinase, protein kinase C-b) and factors relating di-
rectly to cell proliferation cycle (Table 1). Glivec also sup-
pressed protein phosphatase 1 and 2 genes and thus can
stimulate indirectly the activity of other protein kinases. Sig-
niﬁcant overexpression of the following transcripts was
detected in Glivec-treated K-562 cells (Table 2): protein
kinase-related oncogene (PIM2), c-jun proto-oncogene, Pvt-1
oncogene homologue (myc-activator), protein kinase C-a gene,
human basic transcription factor 2 p44 (MAPK activator).
However, Glivec induced an overexpression of several apop-
totic factors as: interleukins 6 and 13, 1-8D gene from inter-
feron-inducible gene family, tumor necrosis factor receptor
superfamily (10b), interferon-inducible protein 9-27, STAT-
induced STAT-inhibitor 2.
In summary, the results from microarray analysis dem-
onstrate that siRNA interference of bcr-abl expression and
inhibition of already synthesized bcr-abl fusion protein by
Glivec are in a cross-talk with several common factors that
might be responsible in major degree for cell death or
for restoration of the cell proliferation after long-term
treatment.
Both, anti-bcr-abl RNAi and Glivec-treatment of K-562
cells decreased in equal degree bcl-2-associated transcription
factor (bcl-2 is one of the major apoptotic signals), and over-
expressed in equal degree c-jun proto-oncogene, protein kinase
C-a, pvt-1 oncogene homologue (myc-activator) (all they are
well-known antiapoptotic factors). It can hypothesized that
bcr-abl oncoprotein participates in the regulation of these
common genes and/or their respective proteins. To guarantee
the success of siRNA interference and Glivec, it is necessary to
clarify the expression of all these factors and to prognosticate
their role in restoration of cell proliferation during long-termtreatment. It did not exclude many other genes to be inﬂuenced
signiﬁcantly during treatment more than 6–8 days as in the
present study. In this context, the combined application of
Glivec (or anti-bcr-abl siRNAs) with other substances directed
to the genes described above is a promising strategy for CML
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